Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATH study: Hizentra (IgPro20) for maintenance treatment of CIDP
2011-003448-28Phase 3Completed
- Sponsor
- CSL Limited
- Start
- Jan 2012
- Countries
- 1
01
Overview
A Phase 3 trial of polyvalent human immunoglobulin in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by CSL Limited. Started Jan 2012; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2011-003448-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003448-28.